Using the MTT Cell Viability Test and Immunocytochemistry Techniques, Benzimidazole's Cytotoxicity and Apoptosis Activation in Mouse 4T1 Cell Culture

Cancer is known as a major health problem globally. Breast cancer is the most common malignant tumor and metastasis continues to be the main cause of poor prognosis. Despite recent advances in cancer treatment, the success of metastatic breast cancer treatment is not at the desired level. Among the anticancer drugs discovered in recent years, various benzimidazole derivatives have attracted attention in the development of anticancer agents due to their various biological activities and clinical applications. The aim of this study was to evaluate the antiproliferative activity of synthesized benzimidazole derivative SA-61 in 4T1 breast cancer cell line in comparison with abemaciclib, which is approved by FDA for the treatment of breast cancer. The antiproliferative activity and apoptotic effect of SA-61 were examined using MTT and immunohistochemical methods, respectively. According to MTT results, compound SA-61 showed antiproliferative activity in 4T1 cells in a dose-dependent manner, but this effect was lower than abemaciclib. Although further studies are needed to specifically identify the compounds involved in its anti-cancer activity, our findings suggest that SA-61 inhibits the proliferation of 4T1 cells and its effect is dose dependent.